Prevalence of elevated liver enzymes and its association with type 2 diabetes: A cross-sectional study in Bangladeshi adults.
Bangladeshi adults
liver enzymes
prevalence
type 2 diabetes
Journal
Endocrinology, diabetes & metabolism
ISSN: 2398-9238
Titre abrégé: Endocrinol Diabetes Metab
Pays: England
ID NLM: 101732442
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
06
12
2019
revised:
22
01
2020
accepted:
25
01
2020
entrez:
23
4
2020
pubmed:
23
4
2020
medline:
23
4
2020
Statut:
epublish
Résumé
Type 2 diabetes (T2D) is a major public health concern affecting millions of people worldwide. The relationship between liver enzymes and T2D has been reported in limited studies; however, there is still a lack of evidence for the Bangladeshi population. This study aimed to evaluate the prevalence of elevated liver enzymes and examine its association with the prevalence of T2D in Bangladeshi adults. A total of 270 individuals (110 diabetic and 160 nondiabetic) were enrolled in the study. Alanine and aspartate aminotransferase (ALT, AST), alkaline phosphatase (ALP) and γ-glutamyltransferase (GGT) activities were measured in blood serum collected from them. T2D was defined as fasting blood glucose (FBG) ≥126 mg/dL or self-reported recent use of insulin or antidiabetic medications. Association between liver enzymes and T2D was evaluated by multinomial logistic regression analysis. Overall, 61.2% of participants in T2D and 37.1% of participants in the nondiabetes group had at least one or more elevated liver enzymes. The mean concentrations of serum ALT, AST, ALP and GGT were significantly higher in the T2D group compared to the nondiabetes group. The prevalence of elevated liver enzymes was significantly higher in the diabetes group compared to the nondiabetes group ( A high prevalence of elevated liver enzymes was observed in subjects having diabetes. Increased serum GGT activity was independently associated with the prevalence of T2D among Bangladeshi adults. More studies of this nature should be carried out in developing countries to get proper insights into the involvement of liver enzymes in T2D.
Sections du résumé
BACKGROUND
BACKGROUND
Type 2 diabetes (T2D) is a major public health concern affecting millions of people worldwide. The relationship between liver enzymes and T2D has been reported in limited studies; however, there is still a lack of evidence for the Bangladeshi population. This study aimed to evaluate the prevalence of elevated liver enzymes and examine its association with the prevalence of T2D in Bangladeshi adults.
METHODS
METHODS
A total of 270 individuals (110 diabetic and 160 nondiabetic) were enrolled in the study. Alanine and aspartate aminotransferase (ALT, AST), alkaline phosphatase (ALP) and γ-glutamyltransferase (GGT) activities were measured in blood serum collected from them. T2D was defined as fasting blood glucose (FBG) ≥126 mg/dL or self-reported recent use of insulin or antidiabetic medications. Association between liver enzymes and T2D was evaluated by multinomial logistic regression analysis.
RESULTS
RESULTS
Overall, 61.2% of participants in T2D and 37.1% of participants in the nondiabetes group had at least one or more elevated liver enzymes. The mean concentrations of serum ALT, AST, ALP and GGT were significantly higher in the T2D group compared to the nondiabetes group. The prevalence of elevated liver enzymes was significantly higher in the diabetes group compared to the nondiabetes group (
CONCLUSIONS
CONCLUSIONS
A high prevalence of elevated liver enzymes was observed in subjects having diabetes. Increased serum GGT activity was independently associated with the prevalence of T2D among Bangladeshi adults. More studies of this nature should be carried out in developing countries to get proper insights into the involvement of liver enzymes in T2D.
Identifiants
pubmed: 32318634
doi: 10.1002/edm2.116
pii: EDM2116
pmc: PMC7170449
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e00116Informations de copyright
© 2020 The Authors. Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest in relation to this manuscript.
Références
Diabetes Obes Metab. 2006 May;8(3):237-49
pubmed: 16634983
Diabetologia. 2003 Mar;46(3):359-64
pubmed: 12687334
BMC Gastroenterol. 2010 Jun 07;10:56
pubmed: 20529259
Diabetes. 2004 Oct;53(10):2623-32
pubmed: 15448093
Am J Med. 1988 Nov 28;85(5A):71-6
pubmed: 3057896
J Histochem Cytochem. 1996 Oct;44(10):1101-8
pubmed: 8813074
Euroasian J Hepatogastroenterol. 2016 Jan-Jun;6(1):1-4
pubmed: 29201714
J Diabetes Complications. 2013 Jul-Aug;27(4):333-9
pubmed: 23683663
Diabetes Metab Res Rev. 2009 Jan;25(1):64-9
pubmed: 19065605
Gastroenterology. 2008 Dec;135(6):1935-44, 1944.e1
pubmed: 19010326
Atherosclerosis. 2005 Feb;178(2):327-30
pubmed: 15694941
J Epidemiol Community Health. 2015 Nov;69(11):1040-4
pubmed: 26139641
J Biol Chem. 2001 Feb 9;276(6):3798-804
pubmed: 11080500
Clin Chem. 1986 Aug;32(8):1593-4
pubmed: 3731466
Diabetes Care. 2005 Nov;28(11):2812
pubmed: 16249570
Nat Rev Endocrinol. 2018 Feb;14(2):88-98
pubmed: 29219149
Diabetes. 2002 Jun;51(6):1889-95
pubmed: 12031978
Diabetes Metab Syndr. 2016 Jan-Mar;10(1 Suppl 1):S147-50
pubmed: 26711007
Diabet Med. 2005 Sep;22(9):1134-40
pubmed: 16108838
Am J Epidemiol. 2013 Jul 15;178(2):159-71
pubmed: 23729682
BMC Endocr Disord. 2008 Jun 05;8:5
pubmed: 18533046
Diabetes Metab. 2005 Dec;31(6):542-50
pubmed: 16357802
J Atheroscler Thromb. 2011;18(3):177-81
pubmed: 21041983
Diabetes Care. 2005 Dec;28(12):2913-8
pubmed: 16306554
World J Gastroenterol. 2013 Feb 14;19(6):802-12
pubmed: 23430039
Metabolism. 2000 Feb;49(2 Suppl 1):27-9
pubmed: 10693917
Diabetol Metab Syndr. 2014 Feb 06;6(1):14
pubmed: 24502834
Diabetes Care. 2007 Mar;30(3):734-43
pubmed: 17327353
Ann Med. 2005;37(5):333-46
pubmed: 16179269
World J Gastroenterol. 2011 Sep 7;17(33):3785-94
pubmed: 21987620
Diabetes Care. 2005 Jul;28(7):1757-62
pubmed: 15983331
J Clin Endocrinol Metab. 2004 Nov;89(11):5410-4
pubmed: 15531490
Diabetes Care. 2004 Jun;27(6):1427-32
pubmed: 15161799
Obesity (Silver Spring). 2007 Jul;15(7):1841-50
pubmed: 17636103
BMC Cardiovasc Disord. 2019 Feb 21;19(1):42
pubmed: 30791868
Diabetes Care. 2018 Jan;41(Suppl 1):S13-S27
pubmed: 29222373
Sci Rep. 2019 Jun 21;9(1):9061
pubmed: 31227765
Diabetol Metab Syndr. 2019 Jun 21;11:49
pubmed: 31285758
Hepatology. 2003 Apr;37(4):917-23
pubmed: 12668987
J Gastroenterol Hepatol. 2016 May;31(5):936-44
pubmed: 26667191
BMC Public Health. 2017 Jul 25;18(1):58
pubmed: 28743284
Postgrad Med. 2016 Nov;128(8):770-776
pubmed: 27681272
PLoS One. 2018 Nov 1;13(11):e0206850
pubmed: 30383816
Clin Chim Acta. 2003 Jan;327(1-2):69-79
pubmed: 12482620
Diabetes Care. 2009 Apr;32(4):741-50
pubmed: 19131466
Bull World Health Organ. 2014 Mar 1;92(3):204-13, 213A
pubmed: 24700980
BMJ Open Diabetes Res Care. 2016 Sep 19;4(1):e000296
pubmed: 27738514
Diabetes Metab. 2008 Jun;34(3):283-9
pubmed: 18486512
CMAJ. 2005 Feb 1;172(3):367-79
pubmed: 15684121
Metabolism. 2008 Mar;57(3):387-92
pubmed: 18249212
J Endocrinol Invest. 2008 Feb;31(2):146-52
pubmed: 18362506